NVP-BHG712

• 产品号: S2202
• CAS号: 940310-85-0
• 分子式: C26H20F3N7O
• 分子量: 503.4785096
• 保 存: -20°C

产品别名

• 标题: NVP-BHG712
• IUPAC标准名: 4-methyl-3-{[1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl]amino}-N-[3-(trifluoromethyl)phenyl]benzamide
• IUPAC传统名: 4-methyl-3-{[1-methyl-6-(pyridin-3-yl)pyrazolo[3,4-d]pyrimidin-4-yl]amino}-N-[3-(trifluoromethyl)phenyl]benzamide

产品登记号

• CAS号: 940310-85-0

产品性质

• 作用靶点: VEGFR
• 作用靶点: SRC
• 作用靶点: c-Abl
• 作用靶点: B-Raf
• 成盐信息: Free Base
• 保存条件: -20°C

产品详细信息

详细说明 (English)

Research Area

• Description: Cancer

Biological Activity

• Description: NVP-BHG712 is a specific inhibitor of c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
• Targets: c-Raf; c-Src; c-Abl
• IC50: 0.395 μM; 1.266 μM; 1.667 μM ^[1]
• In Vitro: NVP-BHG712 treatment also dose dependently leads to the inhibition of RTK autophosphorylation in stable transfected A375 melanoma cells with EC50 of 25 nM and 4.2 μM for EphB4 and VEGFR2, respectively. ^[1]
• In Vivo: In a growth factor-induced angiogenesis model, NVP-BHG712 (3 mg/kg, p.o) significantly suppresses VEGF stimulated tissue formation and vascularization by inhibiting EphB4 forward signaling. Furthermore, NVP-BHG712 (10 mg/kg/kg, p.o.) potently reverses VEGF enhanced tissue formation and vessel growth. NVP-BHG712 (3 mg/kg, p.o.) shows a long lasting exposure with concentrations around 10 μM in plasma as well as in lung and liver tissue for up to 8 hours, and thus results in a long lasting inhibition of EphB4 kinase activity in mice. ^[1]
• Features: Discriminates between VEGFR and EphB4

Protocol

• Protocol: Kinase Assay ^[1]
• In vitro kinase assays: All in vitro kinase assays are performed with recombinant purified kinases either purchased from external vendors or produced in house. To estimate kinase activity both, TR-FRET-based LanthaScreen^TM and Caliper mobility shift are used. In brief, the LanthaScreen^TM assay technology is based on the discrimination between the unphosphorylated substrate and the phosphorylated product by a phospho-specific antibody, binding only to the phosphorylated version of the substrate. Both, antibody and substrate, carry fluorescent labels and the close proximity of the labels in the formed complex allows the measurement of a fluorescence resonance energy transfer (FRET) signal. Reading of the FRET signal in a time-dependent/time-gated manner further improves the assay performance by reducing background fluorescence. For dose–response measurements NVP-BHG712 is pre-diluted in 90% DMSO and 50 nL of compound solutions are dispensed directly into the empty assay plate using a HummingBird nanodispenser. The kinase reactions are started by addition of 4.5 μL ATP solution (4 μM ATP, 20 mM Tris/HCL, 1 mM DTT, 0.03% Tween20, 0.01 mM Na₃VO₄) and 4.5 μL enzyme/substrate mix (100 nM fluorescein poly-GAT), 0.5% bovine serum albumin, 20 mM Tris/HCL, 1 mM DTT, 0.03% Tween20, 0.01 mM Na₃VO₄). Further components of the enzyme/substrate mix are the enzymes as well as MgCl₂/MnCl2 which are adjusted specifically to the requirements of the individual enzyme. After incubation for 60 minutes at r.t. the kinase reactions are stopped by addition of 4.5 μL stop solution (50 mM EDTA pH 8.0, 0.04% NP-40, 20 mM Tris/HCl pH 7.4) followed by 4.5 μL of detection mix (1.72 μg/mL Tb-PY20 antibody), 1% bovine serum albumin, 20 mM Tris/HCl, 1 mM DTT, 0.03% Tween20, 0.01 mM Na3VO4). After incubation for 45 minutes at r.t. plates are analyzed in a BMG PHERAstar plate reader. In the Caliper mobility shift assays kinase reactions are analyzed by microfluidic capillary electrophoresis. The transfer of phosphate from ATP to a short peptide by a kinase causes a change in the net-charge of the peptide by ?2. The charge difference between the unphosphorylated and phosphorylated entities of the peptide can be separated in an electrical field. Using peptides attached with a fluorescent label allows detection and quantification of both forms and hence the calculation of the reaction turnover. For dose–response measurements NVP-BHG712 is pre-diluted in 90% DMSO and 50 nL aliquots of solution are dispensed directly into the empty assay plate using a HummingBird nanodispenser. The kinase reactions are started by addition of 4.5 μL substrate mix consisting of ATP and peptide substrate in assay buffer (50 mM HEPES pH 7.5, 0.02% bovine serum albumin, 1 mM DTT, 0.02% Tween20, 0.01 mM Na_{34, 10 mM beta-glycerophosphate) and 4.5 μL enzyme solution in assay buffer. The peptide concentration is 2 μM in the assays. Concentrations for the enzyme, as well as for MgCl2 and MnCl2 are adjusted specifically to the requirements of the individual enzyme. ATP concentrations are adjusted to the Km values of the specific enzyme. After incubation for 60 minutes at 30 °C the kinase reactions are stopped by addition of 16 μL stop solution (100 mM HEPES pH 7.5, 5% DMSO, 0.1% coating reagent 10 mM EDTA pH 8.0, 0.015% BRIJ35). Stopped kinase reactions are analyzed in a LC3000 reader.}
• Protocol: Animal Study ^[1]
• Animal Models: VEGF-mediated angiogenesis in vivo is induced in a growth factor implant model in mice.
• Formulation: NVP-BHG712 is dissolved in 1-Methyl-2-pyrrolidone (NMP) and then diluted with polyethylene glycol 300 (PEG300) to a final concentration of 10% v/v NMP and 90% v/v PEG300.
• Doses: ≤30 mg/kg
• Administration: Administered via p.o.

References

• References: [1] Martiny-Baron G, et al. Angiogenesis. 2010, 13(3), 259-267.

参考文献

• Martiny-Baron G, et al. Angiogenesis. 2010, 13(3), 259-267.